Achieve Life Sciences (NASDAQ: ACHV) reported Q4 EPS of ($0.55), $0.09 better than the analyst estimate of ($0.64).

Recent highlights:

• Completion of enrollment in 254-subject Phase 2b ORCA-1 trial of cytisinicline in U.S. smokers
• Presented final data from cytisinicline Phase 1/2 multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) study at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
• Initiated a trial to assess the maximum tolerated dose, or MTD, for a single administered oral dose of cytisinicline
• Pediatric waiver agreed by the U.S. Food and Drug Administration (FDA)
• Closed registered direct offering for gross proceeds of $5.6 million

For earnings history and earnings-related data on Achieve Life Sciences (ACHV) click here.